Bartolucci A A, Liu C, Durant J R, Gams R A
Cancer. 1983 Dec 15;52(12):2209-13. doi: 10.1002/1097-0142(19831215)52:12<2209::aid-cncr2820521206>3.0.co;2-6.
Of 209 Hodgkin's disease patients treated at least 6 months with a five-drug combination of induction chemotherapy and having a complete remission, four patients developed acute myelogenous leukemia (AML) as a second malignant neoplasm. The overall relative risk for development of AML is 185.0 (P less than 0.05) and the mean time to occurrence of AML is 5.3 years (median, 5.25 years). When examining patient subgroups, the highest relative risk noted was 338.5 (P less than 0.05) for that group of patients receiving an additional 6 months of postinduction MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone). Patients receiving only 6 months of induction BVCPP (BCNU, vinblastine, cyclophosphamide, procarbazine, and prednisone) had a relative risk of 166.2 (P less than 0.05). These data results are consistent with previous reports that patients treated for Hodgkin's disease are at high risk for development of AML. However, to date, no patients in this series have developed second malignancies other than AML.
在209例接受了至少6个月诱导化疗五药联合治疗且达到完全缓解的霍奇金淋巴瘤患者中，有4例患者发生急性髓系白血病（AML）作为第二原发性恶性肿瘤。发生AML的总体相对风险为185.0（P<0.05），AML发生的平均时间为5.3年（中位数为5.25年）。在检查患者亚组时，接受诱导后额外6个月MOPP（氮芥、长春新碱、丙卡巴肼和泼尼松）治疗的患者组相对风险最高，为338.5（P<0.05）。仅接受6个月诱导BVCPP（卡莫司汀、长春花碱、环磷酰胺、丙卡巴肼和泼尼松）治疗的患者相对风险为166.2（P<0.05）。这些数据结果与先前关于霍奇金淋巴瘤患者发生AML风险较高的报道一致。然而，迄今为止，该系列中尚无患者发生除AML以外的其他第二原发性恶性肿瘤。
